|Bid||5,390.00 x 6100|
|Ask||5,500.00 x 13000|
|Day's Range||5,400.00 - 5,481.00|
|52 Week Range||3,994.50 - 5,520.00|
|PE Ratio (TTM)||20.23|
|Dividend & Yield||2.80 (4.20%)|
|1y Target Est||N/A|
Repare Therapeutics Inc. has corralled $68 million to pinpoint and exploit genetic weaknesses of tumors, an approach showing promise in emerging cancer therapies.
Tesaro's Zejula would likely outperform drugs from Clovis and AstraZeneca in immuno-oncology combinations with Merck, Bristol or Roche.
London-based pharma giant, AstraZeneca plc (AZN) has a strong product portfolio and is one of the key players in the global cardiovascular market.